# Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.

> **NCT07363304** · — · RECRUITING · sponsor: **Meyer Children's Hospital IRCCS** · enrollment: 150 (estimated)

## Conditions studied

- Cystic Fibrosis (CF)

## Interventions

- **DRUG:** Elexacaftor, Tezacaftor, Ivacaftor

## Key facts

- **NCT ID:** NCT07363304
- **Lead sponsor:** Meyer Children's Hospital IRCCS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-02
- **Primary completion:** 2028-11-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07363304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07363304, "Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07363304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*